St. Joseph Hospital of Orange on July 11 enrolled its first patient as part of a national clinical trial conducted by Medtronic Inc. for a renal denervation procedure designed to eliminate treatment-resistant hypertension. St. Joseph Hospital is the only medical center in the Los Angeles/Orange County metro area conducting the clinical trial and is one of only four hospitals statewide conducting the study.
Vascular Solutions, Inc. announced that it has launched its Gel-Block embolization pledgets in the United States for use in the treatment of hypervascular tumors and arteriovenous malformations (AVMs). The company believes its new Gel-Block product represents a major improvement in the precision of sizing, consistency of delivery, and ease-of-use over current embolization practice.
Radiation oncologist, Lizbeth Kenny from Queensland, Australia, showed the way to interventional oncologists at the ECIO meeting (25–28 April, Florence, Italy).
Surefire Medical has announced that it has received 510(k) FDA clearance to market the Surefire High-Flow Microcatheter, the next generation of the company s novel infusion technology. The Surefire system is designed to deliver therapy with higher infusion efficiency than conventional microcatheters to treat primary and secondary liver cancer.
Adam, London, UK, who has been president of every major radiology and interventional radiology association in Europe, including CIRSE, the European Society of Radiology and the Royal College of Radiologists, proposed that an alliance with radiation oncology would benefit both interventional radiologists and radiation oncologists: “the radiation oncologists would gain a ‘surgical arm’ to their armamentarium and the interventional radiologists would gain access to the infrastructure and resident medical staff that they need to look after their own patients.” he said.
Adam, London, UK, who has been president of every major radiology and interventional radiology association in Europe, including CIRSE, the European Society of Radiology and the Royal College of Radiologists, proposed that an alliance with radiation oncology would benefit both interventional radiologists and radiation oncologists: “the radiation oncologists would gain a ‘surgical arm’ to their armamentarium and the interventional radiologists would gain access to the infrastructure and resident medical staff that they need to look after their own patients.” he said.
Teleflex Incorporated has announced its ArrowADVANTAGE5 pressure-injectable peripherally inserted central catheter (PICC) has received FDA 510(k) clearance for central venous pressure (CVP) monitoring indication. The announcement comes in a press release issued through Business Wire.
CVRx, Inc., a private medical device company, has launched today a European post-market hypertension registry to track performance outcomes and physician experience using the company s Barostim neo device for hypertension. The registry is expected to enroll up to 500 patients.
Teleflex Incorporated (NYSE:TFX), a leading global provider of medical devices for critical care and surgery, today announced its ArrowADVANTAGE5 pressure-injectable peripherally inserted central catheter (PICC) has received FDA 510(k) clearance for central venous pressure (CVP) monitoring indication. CVP measurement in patients is one of the most important assessments in determining cardiovascular function. The change in CVP, correlated with the patient s clinical status, is a useful indication of adequacy of venous blood volume and alterations in cardiovascular function. CVP also reflects the pumping ability of the right atrium and ventricle.
AngioDynamics, a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced the publication of a study in the Journal of the American College of Surgeons, titled, "Ablation of Perivascular Hepatic Malignant Tumors with Irreversible Electroporation." The study s authors -- all physicians at Memorial Sloan Kettering Cancer Center -- included Doctors Peter Kingham, Yuman Fong, Ami Karkar, Michael D Angelica, Peter Allen, Ronald DeMatteo, George Getrajdman, Constantinos Sofocleous, Stephen Solomon, and William Jarnagin.
Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced the publication of the results from the CaRES multicenter safety registry for its ultrasound imaging agent DEFINITY(R) Vial for (Perflutren Lipid Microsphere) Injectable Suspension.1 The CaRES (Contrast Echocardiography REgistry for Safety Surveillance) study, found that DEFINITY(R) was well-tolerated in patients of different types undergoing clinically indicated DEFINITY(R)-enhanced echocardiography in a broad range of typical clinical settings. The results were published in the July 2012 issue of the Journal of the American Society of Echocardiography (Weiss et al., 2012).
Vascular Closure Systems, Inc.: 30-Day Follow-Up Results of the First in Human (FIH) Clinical Test Series of the FastSeal(R) Bioabsorbable Vascular Access Closure System - 100% Success Rate, Including Patients with Challenging Anatomy and Vessel Condition. The company is pleased to announce that the 30-Day follow-up results for the Phase I FIH clinicals have been perfect, as confirmed by doppler and ultrasound evaluation. The evaluation confirmed normal vessel healing, with complete absorption of the FastSeal(R) sealing element. During the follow-up, no adverse events were observed - no hematoma, pseudoaneurysm or fistulas were present in any of the patients. All patients were asymptomatic and the comfort of the device was excellent, with no groin pain during the deployment, immediately after, at 7, and 30-days after the procedure.
Robert J Lewandowski, associate professor of Radiology, Northwestern University, Chicago, USA, who was part of the GEST 2012 US scientific programme committee, gave Interventional News a quick account of key developments from the interventional oncology sessions from the meeting in New York. What were the key, new interesting developments in interventional oncology to emerge at GEST 2012 US?
Ultrasonix Medical Corporation has received approval from the US Food and Drug Administration for its SonixGPS technology for Vascular Access procedures.
SIR-Spheres microspheres are well-tolerated and effective internal radiotherapy for unresectable, heavily pre-treated colorectal cancer liver metastases, according to results from a new study of more than 600 patients presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos